Chris Chorley

First Name*

Last Name*

Email*

Phone*

Message*

I am authorized to claim this profile. I agree Eventually may contact me regarding my request.

Your request has been received.
Thank you.

Oops! Something went wrong while submitting the form.

First Name*

Last Name*

Email*

Phone*

Message*

Chris Chorley and Eventually may contact me regarding my request.

Your request has been received.
Thank you.

Oops! Something went wrong while submitting the form.

Contact Chris

Chris Chorley

Associate Director, Global Regulatory CMC

Biogen

Chris Chorley has worked in the UK pharmaceutical industry for approximately 15 years, beginning his career as a Research Scientist for AstraZeneca, before moving into regulatory affairs in 2011.

Talks About
#drugdiscovery #regulatoryaffairs

Preferred Locations
#Europe

Speaking Engagements

Oligonucleotide Therapeutics and Delivery

Paid

Oligonucleotide Therapeutics - the emerging medicine class - are harnessing the therapeutic benefit of targeting genetic material utilising oligonucleotide conjugates, antisense oligonucleotides (ASOs), mRNA and RNAi.

21-22 September 2022

Healthcare

Claim Your Profile Request

Speaker Contact Request

SPEAKER

Chris Chorley

Associate Director, Global Regulatory CMC

Speaking Engagements

Oligonucleotide Therapeutics and Delivery